Review Article

Ferroptosis in Different Pathological Contexts Seen through the Eyes of Mitochondria

V. Otasevic, 1 M. Vucetic, 2 I. Grigorov, 1 V. Martinovic, 1 and A. Stancic 1

1Department of Molecular Biology, Institute for Biological Research "Siniša Stanković," National Institute of Republic of Serbia, University of Belgrade, Serbia
2Medical Biology Department, Centre Scientifique de Monaco (CSM), Monaco

Correspondence should be addressed to A. Stancic; ana.stancic@ibiss.bg.ac.rs

Received 20 January 2021; Revised 8 May 2021; Accepted 25 May 2021; Published 8 June 2021

Academic Editor: Stefano Falone

Copyright © 2021 V. Otasevic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ferroptosis is a recently described form of regulated cell death characterized by intracellular iron accumulation and severe lipid peroxidation due to an impaired cysteine-glutathione-glutathione peroxidase 4 antioxidant defence axis. One of the hallmarks of ferroptosis is a specific morphological phenotype characterized by extensive ultrastructural changes of mitochondria. Increasing evidence suggests that mitochondria play a significant role in the induction and execution of ferroptosis. The present review summarizes existing knowledge about the mitochondrial impact on ferroptosis in different pathological states, primarily cancer, cardiovascular diseases, and neurodegenerative diseases. Additionally, we highlight pathologies in which the ferroptosis/mitochondria relation remains to be investigated, where the process of ferroptosis has been confirmed (such as liver- and kidney-related pathologies) and those in which ferroptosis has not been studied yet, such as diabetes. We will bring attention to avenues that could be followed in future research, based on the use of mitochondria-targeted approaches as anti- and proferroptotic strategies and directed to the improvement of existing and the development of novel therapeutic strategies.

1. Introduction

Despite the progress in medicine during recent decades, diseases such as cancer, neurodegenerative and cardiovascular diseases, and ischemic heart and brain injury still have considerable mortality rates worldwide [1]. In particular, worrying is the fact that the incidence of these illnesses is globally on the rise, pointing to an urgent need for the development of novel and effective therapies. Although diverse treatment strategies have been exploited for each condition, a major concern that still exists is deregulated or adverse cell death in the affected tissues, the hallmark that connects these pathologies at the molecular level. Cell destiny (cell death and cell survival) is under the tight control of mitochondria [2–4]. These organelles regulate a variety of vital cellular activities, including ATP synthesis, intracellular calcium homeostasis, hormone production and responses to hormones, cell differentiation, and cell death [3]. Thus, it is not surprising that defects in mitochondrial activity and/or specific alterations in mitochondria-mediated signalling pathways are also the hallmarks of the above-mentioned diseases [5, 6]. Therefore, targeting mitochondria-mediated pathways aimed at manipulating cell death in diseases has a promising therapeutic potential and is of immense research interest. Apoptosis, as the major pathway of normal cell turnover, has been widely and extensively studied from the aspect of targeting mitochondria as a therapeutic strategy and has proven to be an effective target in many diseases (especially in cancer and neurodegenerative and cardiovascular diseases) [7–10]. Depending on the context, mitochondria-dependent apoptotic approaches can be aimed at apoptosis induction, as in cancer, or its inhibition, as in neurodegenerative and cardiovascular diseases.

Although apoptosis modulation through different strategies has achieved significant success in the treatment of these diseases [8–11], they are still far from being negligible, which suggests that new avenues for the development of clinical regimens need to be examined. One such avenue has been opened with the discovery of a new type of regulated cell death—ferroptosis.
Ferroptosis is a newly detected form of regulated cell death characterized by iron-dependent accumulation of lipid peroxides arising from the iron-catalysed oxidation of polyunsaturated fatty acids that can be pharmaceutically inhibited by iron chelators and lipid peroxidation inhibitors [12]. It differs from apoptosis in the changes of cell morphology and biochemistry [12–14]. On the other side, the molecular pathways and key players involved in ferroptosis are very similar, if not identical to those involved in the induction/mediation of oxytosis or oxidative stress-induced programmed cell death as defined by Tan et al. [15] almost one decade before ferroptosis. Leverenz et al. [16] and Maher et al. [17] have suggested that oxytosis and ferroptosis are two names for the same cell death pathway reviewing the strong evidence for their assertion. Extensive research into the process of ferroptosis during the last few years has revealed that it is linked to different pathological states, such as cancer, neurodegenerative, cardiovascular, and hemato logic diseases, and ischemia/reperfusion (I/R) injury of various organs, including the heart, brain, and kidney [18–23]. Thus, modulating ferroptosis, either by targeted induction (e.g., cancer) or by its prevention (e.g., in neurodegenerative and cardiovascular diseases), might be a promising therapeutic approach, and together with apoptosis modifiers, this has contributed to better understanding of all the above-mentioned diseases and improvement of their treatment. The antipathological rationale is supported by the effects of inducers (erastin, Ras-selective lethal small molecule (RSL)) and inhibitors (ferrostatin-1, liproxstatin-1) of ferroptosis that have been developed thus far, which can successfully modulate cell death in cancer and neurodegenerative and cardiovascular diseases [22, 24]. At the same time, the ability to specifically target mitochondrial pathways to modulate ferroptosis is less exploited. The reason for this lies in the fact that in contrast to the well-defined roles of mitochondria in the regulation of apoptosis, their role in the ferroptotic type of cell death is less well defined [25, 26]. In addition, the results of studies investigating the relationship between mitochondrial functionality and ferroptosis are controversial [12, 20, 27–29], and the lack of consensus as to their actions keeps the debate open.

However, the recently revealed molecular mechanisms of ferroptosis show that the involvement of mitochondria in the regulation of this type of cell death has become more important and points to further directions in research.

Specifically, the crucial role of mitochondria in lipid peroxidation-driven ferroptotic cell death has been observed in the following conditions: (i) impaired mitochondrial metabolism and ensuing extensive production of reactive oxygen species (ROS), (ii) excess free-iron accumulation in mitochondria, and (iii) mitochondrial cysteine deprivation [27, 28, 30]. Along these lines, the prevention of these mitochondrial states significantly correlates with increased resistance to ferroptotic cell death [28, 30–32]. Great progress has been made in the protection of cardiomyocytes and neuronal cells from the inducers of lipid peroxidation and ferroptosis by blocking mitochondria-dependent ferroptosis pathways using specific mitochondria-targeted ROS scavengers, antioxidants, and modulators of mitochondrial iron levels [12, 28, 32–35]. In the reverse approach aimed at sensitizing cancer cells (e.g., hepatocarcinoma) to their demise, the anticancer activity of erastin, an inducer of ferroptosis, was mediated by mitochondrial pathways that involve voltage-dependent anion channel (VDAC) opening, mitochondrial hyperpolarization, consequent increase in ROS production, and mitochondrial dysfunction [36, 37]. In addition, since mitochondrial morphology and functional activity coexist in an intimate structure/function relationship [38–40], along with the characteristic phenotype of mitochondria in ferroptotic cells, mitochondrial function in ferroptosis is compromised [27, 31] and rescuing or damaging mitochondrial function can affect the outcome of ferroptosis.

Taking all these considerations into account in addition to the well-known contributing role of mitochondria to many different pathologies, we have reviewed the existing knowledge of the role of these organelles in the process of ferroptosis in disease states, primarily in cancer and neurodegenerative and cardiovascular diseases. We will also discuss the potential implementation of specific mitochondria-targeted approaches for modulating ferroptotic cell death beyond these diseases and in other pathological conditions that are accompanied by increased cell death and/or impaired mitochondrial function. Finally, we will present future directions in the examination of various mitochondria-targeted approaches for modulating (through either induction or suppression) ferroptosis with the aim of improving the understanding and targeted therapy of the discussed diseases.

2. Ferroptosis: The Basic Signalling Pathways and Its Hallmarks

Ferroptosis is an iron-dependent, lipid peroxide-driven form of cell death that differs from other forms of regulated cell death with respect to the biochemical pathways, the main triggers and executors, and morphological features. Since 2012 when the Stockwell Group first recognized ferroptosis as a new form of cell death, evidence in support of its uniqueness has increased [12]. The main event in ferroptosis is the uncontrolled accumulation of lipid peroxides as a result of an imbalance in their production and removal. Two major pathways lead to lipid peroxide formation: enzymatic and nonenzymatic [41]. The former involves enzymes that catalyse the metabolism of arachidonic acids and polyunsaturated fatty acids (PUFAs), with the central role assumed by lipox ygenases (LOXs). The latter is a redox-based mechanism of lipid peroxide production. This process is triggered when ROS, reactive nitrogen species (RNS), or reactive lipid species (RLS) extract a hydrogen atom from a PUFA, forming a lipid radical (L’). [41]. The hydroxyl radical (‘OH) and the hydroperoxyl radical (’OOH) are the strongest initiators of this process. They are formed in the reaction of ferrous iron (Fe2+) with hydrogen peroxide (H2O2) in the Fenton reaction [41]. Regardless of the pathways that lead to the initiation of lipid peroxidation, this process moves on to the second and third phases, propagation and termination, respectively [42]. In the propagation phase, L’ rapidly reacts with oxygen to form a lipid peroxy radical (LOO’), which extracts a
hydrogen atom from another lipid molecule, generating a new \( \cdot O_2^- \) (which continues the chain reaction) and a lipid hydroperoxide (LOOH) [41]. Once lipid peroxidation is initiated, propagation of chain reactions occurs until the termination products are produced. The lipid peroxides produced during the propagation phase can be converted into hydroxy fatty acids or reactive aldehydes that initiate lipid peroxidation themselves and thus the chain reaction [42].

However, it is unclear how lipid peroxidation leads to ferroptotic cell death. It is likely that cell death is the result of multiple events, including direct damage to specific membranes and the activation of downstream pathways [43–45]. Membrane lipid peroxidation induces its disruption and changes physical properties, decreasing membrane fluidity, increasing membrane permeability, disturbing the ion gradient, and slowing down lateral diffusion [46–49]. Furthermore, the formation of secondary products of lipid peroxidation of PUFAs can modulate protein functions and several signalling pathways that interfere with cell death [50, 51]. Among these, malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) are the most abundant and exhaustively studied in the context of other types of cell death, apoptosis and necrosis [52]. It was shown that these aldehydes accumulate in different models of ferroptosis [14, 53, 54], but their significance in this type of cell death needs to be defined.

Under basal conditions, the lipid peroxidation cascade is controlled by the antioxidant enzyme glutathione peroxidase 4 (GPX4) that uses glutathione (GSH) to reduce lipid peroxides to their alcohol form (LOOH). GSH-GPX4, or more precisely the axis involving cysteine-GSH-GPX4-lipid peroxides, constitutes the backbone of ferroptosis signalling [55]. GSH is a simple tripeptide with cysteine playing an important role in redox state regulation due to its reactive thiol. In addition to its role as a cofactor for GPX, two more aspects of GSH action are relevant to ferroptosis: (i) regulation of the activity and intracellular translocation of LOXs [15, 56] and (ii) the redox cycling activity of Fe\(^{2+}\) [45, 57]. Depletion of GSH increases both LOX activity and membrane translocation as well as the substrate of the Fenton reaction. Also, GSH is a cofactor for glutathione S-transferase (GST) in the reaction of detoxification of both ROS and xenobiotics [58].

Cells obtain cysteine from the extracellular environment in the oxidized (dominant) form, cystine, through the cystine/glutamate antiporter, xCT. In the cell, cystine is reduced to cysteine via cysteine reductase and “incorporated” into GSH through enzymatic reactions catalysed by glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS). Consequently, one approach for ferroptosis induction involves the targeting of xCT. Erastin has been widely used as a pharmacological modulator/inducer of ferroptosis [59]. Initially, erastin was described as an antitumor compound that induces cell death in RAS-overexpressing cells [60]. Subsequently, it was reported that erastin exhibits an inhibitory activity over VDAC [37] and xCT [12]. Although both these actions of erastin are related to ferroptosis induction, it is likely that inhibition of VDAC2 and VDAC3 is necessary but not sufficient for erastin-induced death [37]. It is believed that targeting of the system xCT plays a major role in the process of ferroptosis induction by erastin [12]. However, the effect of erastin on VDAC is relevant in the context of the role of mitochondria in ferroptosis, as discussed above. Besides these pharmacological approaches that target xCT and cystine/glutamate metabolism, natural triggers that induce ferroptosis in physiological contexts have been described. One is the accumulation of extracellular glutamate [12, 20]. Glutamate-induced toxicity has been extensively studied in HT22 cells, a specifically designed mouse hippocampal nerve cell line that is particularly sensitive to glutamate and is killed exclusively via the oxidative pathway called oxtosis [61]. The first step in this cell death is glutamate-induced inhibition of cystine uptake through xCT [62]. The same pathway of glutamate-induced cell death has been recently described in the context of ferroptosis [63, 64]. The second “natural” approach that can induce ferroptosis is cysteine deprivation, which triggers ferroptosis through GSH depletion [27, 65]. Gao et al. [27] showed that a cysteine-free medium induces cysteine and GSH depletion and results in ferroptosis of the HT1080 cell line.

Ferroptosis can also be pharmacologically induced by inhibition of GPX4 activity with the commonly used inhibitor RSL [59]. Also, the suppression of GSH synthesis by GCL inhibition with buthionine sulfoximine (BSO) in some cases represents a successful approach in ferroptosis induction [55].

In addition, an important regulatory point and therefore a target for ferroptosis modulators is the metabolism of iron, which is, as previously mentioned, a crucial player in the initiation of lipid peroxidation (Fenton reaction). Thus, the imbalance of intracellular iron homeostasis in favour of iron overload is pivotal in the induction of ferroptosis [33, 66, 67], while iron chelators such as deferoxamine (DFO) have been used for its inhibition [35, 68]. The molecular machinery dedicated to ferroptosis with possible targets for its modulation is presented in Figure 1.

Morphological changes related to ferroptosis also make this type of cell death unique and recognizable when compared to other types of cell death—apoptosis, necrosis, and autophagy. Ferroptosis is characterized by the so-called “ballooning” phenotype [69, 70], observed as a characteristic rounded morphology of the cell surface. This seems to be the result of several morphological alterations, including destabilization of the plasma membrane, disturbed proteostasis, and rearrangement of the cytoskeleton [71–73]. Also, ferroptotic cells exhibit extensive ultrastructural changes in the mitochondria, with the mitochondria being smaller than normal with an increased bilayer membrane density [12, 37]. There are reduction in volume, disruption of the outer mitochondrial membrane, and loss of mitochondrial cristae [44, 69]. This is clearly different when compared to apoptosis, where no significant changes in mitochondrial structure are observed, and to necrosis, in which the swelling of organelles, including the mitochondria, has been observed [23]. In addition, none of the characteristic morphological features related to necrosis (cytoplasmic swelling, plasma membrane rupture), apoptosis (chromatin condensation and margination), or autophagy (formation of double-
membrane enclosed vesicles) have been associated with ferroptosis [12, 13, 19, 36].

The fact that ferroptosis cannot be inhibited by the classical inhibitors of apoptosis, autophagy, and necrosis [44] establishes the uniqueness of ferroptosis, not only from apoptosis but also from other types of cell death.

3. Mitochondria-Dependent Pathways in Ferroptosis

Although knowledge about the mechanisms mediating ferroptosis is constantly growing, there is still no consensus regarding the specific contribution of each organelle to the initiation and execution of this type of cell death. Current data argue that lipid peroxidation localized in the endoplasmic reticulum, lysosomes, Golgi apparatus, and mitochondria can be involved in signalling related to ferroptosis [20].

As an integrative place for many intracellular and extracellular signals, the mitochondria play a central role in determining cell destiny [3]. Their essential role in the regulation of apoptosis and necrosis has been confirmed through decades of examination of these types of programmed cell death [3, 4]. Although changes in mitochondrial morphology represent one of the criteria for the definition of ferroptosis and its distinction from other types of cell death [12], as we stated above, the contribution of mitochondrial metabolism to the triggering and execution of ferroptosis is still a matter of debate. Several aspects of mitochondria-related metabolism predispose this organelle to the induction of ferroptosis, including metabolism of energy substrates (especially lipids) and accompanying ROS production, as well as the metabolism of amino acids (glutamine) and iron (summarized in Figure 2).

Mitochondria play an important role in lipid metabolism. Citrate synthase (CS) and acyl-CoA synthetase family member 2 (ACSF2), which are localized in the mitochondria, regulate fatty acid activation and synthesis and thus provide precursors for lipid peroxidation. These enzymes have been recognized as important mediators of erastin-induced ferroptosis [12]. In addition to fatty acids, the metabolism of glutamine, a nonessential amino acid, might provide precursors for the tricarboxylic acid (TCA) cycle, especially in states of increased metabolic demand such as cancer [74]. Enzymes important for the catalysis of glutaminolysis are localized in the mitochondria. Regardless of the source of the precursors, the increase in TCA and oxidative phosphorylation (OXPHOS) leads to ROS accumulation in the mitochondria, which supports their active role in triggering ferroptosis [75].

Figure 1: The main cellular pathways related to ferroptosis and potential targets for its manipulation (induction or inhibition). The main regulatory pathway of ferroptosis involves the cysteine-GSH-GPX4-lipid peroxide axis. Cysteine is transported into the cell via xCT in its oxidized form (cystine). One of the main roles of cysteine is the synthesis of glutathione (GSH), a process in which the key-limiting step is catalysed by glutamate-cysteine ligase (GCL). GSH serves as a cofactor of glutathione peroxidase 4 (GPX4), which reduces lipid peroxides to their alcohol form. Alternatively, lipid peroxides can be reduced by ubiquinol residing in the membrane compartments of the cell. In this way, produced ubiquinone is reduced back to its alcohol form by the action of ferroptosis-suppressor protein 1 (FSP1). The central event in the lipid peroxide production pathway is the Fenton reaction, a reaction between Fe²⁺ and H₂O₂. The iron is imported into the cell as an iron-loaded transferrin-transferrin receptor 1 (TFR1) complex via receptor-mediated endocytosis. In the endosome (an acidic environment), free Fe²⁺ is converted to Fe³⁺ by the transmembrane metalloeductase STEAP3 and released into the cytoplasm via the divalent metal transporter 1 (DMT1). Red arrows represent potential activators of ferroptosis: (i) inhibitors of xCT (erastin, sulfasalazine), (ii) the inhibitor of GSH biosynthesis and GCL (buthionine sulfoximine (BSO)), and (iii) the inhibitor of GPX (Ras-selective lethal 3 (RSL3)). Green arrows represent potential ferroptosis inhibitors: (i) alternative source of cysteine (N-acetylcysteine (NAC)) and (ii) lipid peroxide scavengers (vitamin E, ferrostatin-1). This figure was created using Servier Medical Art templates, which are licensed under the Creative Commons Attribution 3.0 Unported License (https://smart.servier.com).
The electron transport chain- (ETC-) mediated ROS production has been described as important for cell death in the state of GSH depletion, such as treatment with glutamate and cystine deprivation [15, 27, 76]. Tan et al. [15] have shown that ROS production and the death of HT22 cells induced by glutamate (subsequently named oxtysis) can be inhibited by ETC inhibitors or uncouplers (FCCP, carbonyl cyanide-p-(trifluoromethoxy) phenylhydrazone) that dissipate the mitochondrial membrane potential [77]. Similar changes have been shown recently in the case of ferroptosis induced by cystine depletion [27]. Important data relevant to this issue were published recently by Homma et al. [30]. The authors provided direct evidence that the superoxide anion radical produced by complex III is pivotal for cysteine starvation-induced ferroptosis; they found that the specific inhibitor of complex III, but not of complex I, protects mouse hepatoma Hepa 1-6 cells from ferroptosis in this condition.

In addition to the nonenzymatic production of ROS in OXPHOS, some enzymes localized in the mitochondria such as monoamine oxidase, NADPH oxidase 4 [78], α-ketoglutarate dehydrogenase, and α-glycerophosphate dehydrogenase [79] could contribute to increased ROS production in mitochondria. These enzymes have been proposed as mediators of RSL3-induced ferroptosis since RSL3 increases the level of the mitochondrial-specific ROS probe MitoSOX [25, 35], but this effect is not inhibited by ETC inhibitors [27].

Mitochondria also play an important role in iron metabolism. There are several iron homeostasis-regulating molecules in the mitochondria, including mitoferrin, the ABC transporter, and VDAC, all of which have been connected to ferroptosis (reviewed by Wang et al. [26] and Battaglia et al. [65]). VDAC is an important mitochondrial porin that regulates the influx and efflux of many mitochondrial metabolites in addition to iron and thereby several aspects of mitochondrial metabolism, including mitochondrial membrane potential, Ca2+ overload, and ROS production [80]. VDAC has been recognized as a target of some antiferroptotic approaches such as erastin, erastin-like lead compounds [36, 37], and RSL5 [81]. Cells expressing more VDAC protein were more sensitive to erastin [36]. Calcium chelators effectively counteract erastin-induced cell death in LUHMES.
cells [82], confirming hyperpolarization of the mitochondrial membrane in ferroptosis. It was also shown that the suppression of two genes encoding the critical steps of mitochondrial iron-sulphur cluster (ISC) biosynthesis, NFS1 and ABCB7, leads to an increase in intracellular free iron and promotes cell death by ferroptosis [83].

Apart from the pathways connected to the fundamental role of mitochondria in cells, there are some specific factors that might link mitochondria and ferroptosis. One of these is BID, a proapoptotic protein of the Bcl-2 family, whose translocation into the mitochondria has been shown to mediate erastin-induced ferroptosis in neuronal cells [25]. Also, the flavoprotein apoptosis-inducing factor mitochondria-associated 2 (AIFM2) has recently been recognized as an important antiferroptotic factor involved in maintaining the antioxidant activity of coenzyme Q in the membrane compartment of the cell and has been renamed ferroptosis suppressor protein 1 (FSP1) [14, 84]. It is interesting to note that FSP1 could be seen as an alternative to the GSH-GPX4 part of the ferroptosis-regulating axis, providing protection against the accumulation of lipid peroxides even in conditions of GSH depletion [70].

Growing evidence points to the relevance of oxidation of the mitochondrial membrane in ferroptosis induction/execu-
tion [19, 28]. Friedmann Angeli et al. [19] provided direct evidence that the oxidation of mitochondrial membranes is important for the execution of ferroptosis. They found an accumulation of oxidized mitochondria-specific phospholipid cardiolipin in the kidney of GPX4-knockout mice. In this context, mitochondrially localized GPX4 plays an important role in protection from ferroptosis [85]. The presence of GPX4 in mitochondria at the side of cytochrome c release and its protective role in apoptosis have been previously shown [86].

4. The Role of Mitochondria in Ferroptosis Induction in Cancer

The possibility to interfere with ferroptosis signalling pathways and to manipulate this type of cell death might be of great importance in cancer therapy. There is hope among cancer researchers that ferroptosis induction could be a successful anticancer approach since many cancer types that are resistant to conventional chemotherapy appear to be sensitive to ferroptosis [87, 88]. An important example is pancreatic ductal adenocarcinoma (PDAC) that is resistant to many cancer therapies. As was recently reported in in vitro and tumour xenograft studies [68, 89], the inhibition of xCT leads to an increase in intracellular free iron and promotes cell death by ferroptosis [83].

In the initial characterization of ferroptosis, Dixon et al. [12] reported that mitochondrial DNA- (mtDNA-) depleted $\rho^0$ (Rho0) cells remained sensitive to oxidative stress and ferroptosis induction in the fibrosarcoma cell line, HT1080. This was confirmed in their work on mitochondria-depleted HT1080 cells generated by a mitophagy protocol [29, 94]. These cells exhibited similar sensitivity to ferroptosis-modulating agents (the inducers erastin and RSL1 and inhibitors ferrostatin-1 and iron chelators) as their counterparts harbouring mitochondria. Furthermore, Ye et al. [95] showed that erastin-induced ferroptosis in a leukaemia cell line did not involve changes in mitochondria-mediated ROS generation. Although the data suggest that mitochondria are not required for cancer-associated ferroptosis, these results are somewhat surprising considering all the above-discussed aspects of mitochondrial metabolism that should interfere with the ferroptotic process.

It is likely that contradictory results on the involvement of mitochondria in ferroptosis are due to different methods for measuring both mitochondrial function and cell death, as well as differences between cancer cells. Using Rho0 cells might not be the best method for investigating the significance of mitochondria in cell death processes because Rho0 cells are generated by long-term cultivation with ethidium bromide that frequently induces damage of nuclear DNA [96]. This could affect the response of the cells to oxidative stress-inducing agents, including different ferroptosis inducers. Furthermore, it seems likely that there are differences between various Rho0 cancer cell lines in their sensitivity to ferroptosis. In contrast to the Rho0 fibrosarcoma cell line that shows similar sensitivity to ferroptosis-inducing agents to that of parental cells (as described above and in Dixon et al. [12]), Rho0 cells established from human cervical cancer and oral squamous cell carcinoma cell lines display more sensitivity to $H_2O_2$-induced ferroptosis, along with increased levels of $OH, Fe^{2+}$, and lipid peroxidation [97, 98]. These results have highlighted the relevance of mitochondrial dysfunction in ferroptosis induction in cancer and must be considered during the development of new anticancer ferroptosis-based approaches.

Increasing evidence suggests that mitochondrial metabolism may be of functional relevance to ferroptosis progression and final execution in cancer cells. For example, acyl-CoA synthetase long-chain family member 4- (ACSL4-) dictated ferroptosis in breast cancer cells is accompanied by changes in mitochondrial morphology [14]. Literature also suggests that erastin-induced anticancer activity might be mediated by mitochondria [36, 37]. For example, DeHart et al. [36] have shown that erastin-induced cell death in a hepatocarcinoma cell line involves VDAC opening and mitochondrial hyperpolarization, followed by increased ROS production, mitochondrial dysfunction, and finally a collapse of
the transmembrane potential. Using RNAi-based loss-of-function screening in lung cancer cell cultures and tumour xenografts, Alvarez et al. [83] showed that the suppression of two genes encoding critical steps of mitochondrial ISC biosynthesis, NFS1 and bcl7, leads to iron release from intracellular stores and promotes cell death by ferroptosis. ISCs, as critical components of the OXPHOS complexes and many other metabolic enzymes, are fundamental to the normal functioning of mitochondria, especially at high concentrations of O2. The downregulation of NFS1 (i) induces loss of essential cell functions due to cofactor depletion and (ii) sensitizes cells to ferroptosis by activating the iron starvation response and iron overload.

It was recently shown that the mitochondria only play a role in cysteine deprivation-induced ferroptosis but not in ferroptosis induced by GPX4 inhibition [27]. As the authors explained, this is probably because the mitochondrial function upstream of GPX4 promotes the exhaustion of GSH under cysteine deprivation conditions. In contrast to Dixon’s laboratory, Gao et al. [27] observed that depletion of the mitochondria through parkin-mediated mitophagy or inhibition of OXPHOS dramatically decreased the sensitivity of cells to cysteine deprivation-induced ferroptosis. In most cancer cells, the rate of glutaminolysis is increased to meet their bioenergetic requirements [73]. However, this could make cancer cells more vulnerable to ferroptosis induction. Under cysteine deprivation, glutaminolysis promotes mitochondrial respiration and rapid exhaustion of GSH by GPX4, rendering these cells dependent on the cysteine-GSH supply and thus prone to ferroptosis. Recently published data also speak in favour of the significance of mitochondrial metabolism in the execution of ferroptosis in cancer cells. Namely, it has been suggested that the rerouting of tumour cell metabolism from glycolysis to OXPHOS could make cells more vulnerable to GSH depletion and ferroptosis [99].

A significant amount of data suggests that mitochondria and mitochondria-related signalling could be a promising target in terms of ferroptosis induction as an anticancer therapeutic strategy. However, further studies are needed to establish specific targets and approaches for their manipulation, as well as the specificity and sensitivity of different tumours to such manipulations.

5. Mitochondria and Ferroptosis in Cardiovascular Diseases

Myocardial infarction and heart failure are cardiovascular diseases with the highest mortality rates worldwide [10]. A crucial pathogenic factor in the development of both pathologies is the loss of terminally differentiated cardiomyocytes [10, 100, 101]. Pharmacological and genetic manipulations indicate that cardiomyocyte cell death is the central event in the pathogenesis of both diseases [10, 100, 101]. In addition to apoptosis and necrosis, ferroptosis has recently emerged as an important cause of cardiomyocyte death, at least in I/R heart injury [31, 33, 102]. Moreover, the mechanisms of cardiomyocyte ferroptotic cell death appear to involve mitochondria-dependent pathways [31, 33]. This is quite reasonable considering that mitochondria have previously been described as essential to proper cardiomyocyte functioning [103, 104].

A study performed by Fang et al. [33] demonstrated that the increase in free iron as the result of heme degradation drives ferroptosis of cardiomyocytes in apoptosis- and/or necroptosis-defective Ripk3−/−, Mlkl−/−, or Fadd−/−Mlkl−/− mice exposed to the DNA-damaging agent doxorubicin or in the I/R condition. It was shown that excess free iron accumulates in the mitochondria, not in the cytoplasm, and causes lipid peroxidation specifically in mitochondrial membranes. The authors further showed that the inhibition of pathways that mediate mitochondria-driven ferroptosis (after treatment with a specific mitochondria-targeted antioxidant, Mito-TEMPO) significantly ameliorated doxorubicin-induced lipid peroxidation and cardiac ferroptosis. Moreover, Mito-TEMPO but not TEMPO, a nonspecific antioxidant, significantly reduced doxorubicin-induced cardiomyopathy, assessed by measuring the heart/body weight ratio, serum levels of myocardial enzymes, and cardiac hypertrophy biomarkers. These data clearly showed that oxidative damage of mitochondria is the major consequence of iron overload in I/R-induced heart damage and suggest that the decrease in mitochondrial iron accumulation and/or inhibition of lipid peroxidation may be cardioprotective during both acute and chronic cardiac I/R.

Apart from the above-described role of mitochondria in cardiac I/R injury-associated cardiomyocyte ferroptosis, another study performed by Feng et al. [31] revealed additional mitochondria-dependent mechanisms that could be involved in the execution of ferroptosis. The authors showed that postsischemic application of liproxstatin-1 to the mouse myocardium decreased I/R injury, as shown by the decreased size of the infarct-affected area. Importantly, they found that the observed cardioprotective effects of liproxstatin-1 were achieved through maintenance of mitochondrial structural and functional integrity. The precise mechanism of the beneficial effects of liproxstatin-1 on mitochondria involves the reduction of VDAC1 level and its oligomerization, without affecting VDAC2/3, as well as a decrease in mitochondrial ROS production by the ETC complex I (NADH:ubiquinone oxidoreductase). These results are in agreement with studies postulating that mitochondrial ROS generation is a significant contributor to ferroptosis [105, 106]. This contrasts with the often-represented standpoint that mitochondrial damage is a secondary event in ferroptosis [13, 80] and also opposes studies that did not observe changes in complex I ROS production in erastin-induced or ferrostatin-inhibited ferroptosis [12, 63], suggesting that the impact of mitochondrial ROS on ferroptosis might be dependent on the specific inducer or inhibitor of ferroptosis used. In any case, the results of Feng et al. [31] revealed the antiferroptotic and cardioprotective effects of liproxstatin-1 via direct mitochondrial pathways.

These discoveries raise the possibility of attenuating cardiomyocyte cell death through the manipulation of the
mitochondrial signalling pathways and may provide novel therapies for common and highly lethal heart diseases.

6. Mitochondria and Ferroptosis in Neurodegenerative Diseases

All neurodegenerative diseases are characterized by the progressive and irreversible loss of neurons from specific regions of the central and peripheral nervous systems, followed by a decline in neuronal, motor, and/or cognitive functions [107]. It was shown that cellular death driven by increased levels of iron, ROS, and consequent lipid peroxidation—ferroptosis—is an important contributor to neural cell death in Alzheimer’s, Parkinson’s, and Huntington’s diseases, multiple sclerosis, and acute brain injury caused by cerebral ischemia, haemorrhagic insults, or brain trauma [108–111]. In addition, more recent studies have suggested that mitochondrial damage might be the ultimate step in ferroptosis-related oxidative cell death in neurodegeneration [112]. It was shown that brain regions with the highest levels of iron and ROS accumulation are associated with excessive mitochondrial damage, clearly linking the loss of mitochondrial integrity and function to oxidative neuronal death and neurodegeneration [112].

The first suggestion that the process of ferroptosis in neurodegenerative diseases is regulated by mitochondria came from the research of Gao and Chang [21] who showed the involvement of mitochondrial ferritin in the regulation of brain iron homeostasis and oxidative neuronal cell death, while Wang et al. [32] demonstrated the protective role of mitochondrial ferritin in erastin-induced ferroptosis. Iron accumulation in mitochondria is also found in ferroptosis related to Friedreich’s ataxia where the mitochondria-targeted antioxidant XJB-5-131 was found to be effective in inhibiting ferroptosis [34].

The involvement of mitochondria in neurodegeneration-associated ferroptotic cell death is further demonstrated in PC12 cells where the induction of ferroptosis by tert-butyl hydroperoxide (t-BHP) was accompanied by a decrease in the mitochondrial membrane potential, decreased ATP production, and an increase in mitochondrial ROS [112]. Moreover, in the same model system, it was observed that apart from suppressing ferroptosis, ferrostatin-1 also “repaired” mitochondrial dysfunction, strongly indicating that mitochondrial dysfunction is closely related to ferroptosis [112]. These results are in line with the data of Jelinek et al. [35] who reported that in addition to ferrostatin-1, other ferroptosis inhibitors are also capable of preventing mitochondrial damage in neuronal HT-22 cells and of decreasing ferroptosis induced by RSL3-dependent inhibition of GPX4 and the generation of damaging free radicals. The authors [35] established that in neuronal HT22 cells, RSL3 mediates the concentration-dependent inhibition of GPX4 followed by lipid peroxidation, enhanced mitochondrial fragmentation, reduction of mitochondrial membrane potential, and respiration, while ferroptosis inhibitors, such as DFO, ferrostatin-1, and liproxstatin-1, but also CRISPR/Cas9 Bid knockout and the BID inhibitor BI-6679, protected against RSL3 toxicity. They presented new data that the mitochondria-targeted ROS scavenger mitoquinone (MitoQ) preserved mitochondrial integrity and function, as well as cell viability despite significant loss of GPX4 expression accompanied by an increase in general lipid peroxidation after exposure to RSL3.

Apart from the in vitro data indicating that rescuing mitochondrial integrity and function might be effective in the prevention of ferroptosis in neural cells, the involvement of mitochondria and ferroptosis in neurodegenerative diseases has been supported by results obtained in studies performed in vivo on experimental animals [113–115]. It was shown that the expression of all three GPX4 isoforms is reduced in both the brain of multiple sclerosis patients and the spinal cord of animals with an experimental autoimmune encephalomyelitis (EAE) [115]. The detected decrease in GPX4 in EAE was accompanied by morphological changes in the mitochondria characteristic for ferroptosis, including an irregular matrix, disrupted outer membrane, and reduced or absent cristae [115]. In addition, in the experimental model of arsenite-induced neuronal cell death that was shown to be associated with various neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as amyotrophic lateral sclerosis (ALS), it was shown that the loss of neurons is caused by the accumulation of ROS and characteristic ferroptotic events, including mitochondrial VDAC-related pathways [114]. Although specific identification of ferroptosis in vivo is hampered by lack of specific biomarkers, it was shown that conditional ablation of GPX4 to the forebrain neurons of adult mice causes hippocampal degeneration resembling Alzheimer’s disease and cognitive impairments accompanied by lipid peroxidation and mitochondrial impairments consistent with ferroptosis [113]. This can be partly rescued by inhibitors of ferroptosis, confirming ferroptosis involvement.

All the above data indicate that rescuing mitochondrial integrity and function might be effective in the prevention of ferroptosis in neural cells and provide a new approach in targeting cell death in neurodegenerative conditions. Therefore, mitochondria-dependent mechanisms of ferroptosis in the nervous system need to be fully explored in future research.

7. Ferroptosis in Other Pathologies and the Involvement of Mitochondria

The list of pathologies that involve ferroptosis as an underlying mechanism of their aetiology and progression is growing, as is knowledge about the signalling pathways regulating this type of cell death. In this context, ferroptosis has been established as a contributing factor to tissue damage in ischemic injury of the kidney and in liver diseases [18, 19, 63], in addition to the previously described contribution of apoptosis and necrosis [116–119]. Ferroptosis is also involved in liver haemochromatosis [120] and mediates the activity of anticancer drugs commonly used in hepatocellular cancer therapy (for example, sorafenib) [121]. Although it was initially suggested that ferroptosis was responsible for acetaminophen- (APAP; paracetamol) induced liver injury [122, 123], recently published papers argue against this hypothesis [124, 125]. Jäescue et al. [125] critically reviewed this issue
and suggested that there is no evidence for a quantitatively sufficient amount of lipid peroxides to cause cell death, and thus, APAP hepatotoxicity is not caused by ferroptosis. At the same time, the authors did not exclude the significance of mitochondrial oxidative stress (peroxynitrate) in APAP-induced hepatotoxicity.

Mitochondrial dysfunction plays a critical role in the pathogenesis of different liver and kidney diseases [126, 127], but it is usually linked with tissue injury due to apoptosis, rarely ferroptosis. One of these rare examples comes from studies of an in vitro model of kidney I/R injury that showed that erastin-induced ferroptosis in human kidney-2 (HK-2) cell lines was mediated by changes in mitochondrial metabolism, such as hyperpolarization of the mitochondrial membrane [128] or interaction with a specific mitochondrially localized protein ALR (augmenter of lipid regeneration) [129]. Acute renal failure induced by GPX4 inactivation is accompanied by the accumulation of oxidized cardiolipin in mitochondria and consequent ferroptosis [19].

Scarce data on the role of mitochondria in liver and kidney disease-related ferroptosis, along with the significant impact of this process on their pathogenesis, has opened the field for further examination, with the final aim of producing novel mitochondria-targeted antiferroptotic approaches for the treatment of different pathologies.

8. Ferroptosis in Metabolic Disorders: Possible Implication in Diabetes

In addition to the previously mentioned diseases, mitochondrial dysfunction plays an important role in the pathogenesis of metabolic disorders, such as obesity, metabolic syndrome, and diabetes. The involvement of cell death (apoptosis, necrosis, and autophagy) in diabetes and its link with mitochondrial dysfunction are well documented [117, 130, 131]. To date, there are no studies confirming the role of ferroptosis in the regulation of β-cell mass and the pathology of tissues in the diabetic state. However, there are several peculiarities that characterize the diabetic phenotype, and the pancreas itself, that speak in favour of the possible involvement of ferroptosis in the aetiology and pathogenesis of this disease.

First, the production of ROS is increased in the diabetic state, especially at the mitochondrial level, due to (i) hyperglycaemia, (ii) hyperlipidaemia, (iii) hyperinsulinemia, and (iv) iron overload [132–135]. Along with the increase in the production of ROS, the antioxidative defence is decreased in many diabetes-targeted tissues [136, 137]. This leads to an increase in oxidative pressure commonly seen as an increase in the level of lipid peroxidation end products, suggesting that the GPX4-GSH antioxidant axis is compromised in this condition [138, 139]. Along with this, β-cells are extremely sensitive to oxidative insults due to the intrinsically low expression and activity of antioxidative enzymes, including GPX [140]. In line with the hypothesis that β-cells are prone to ferroptosis, the recent paper from Bruni et al. [68] argues that the viability and function of pancreatic β-islets in vitro are highly compromised in the presence of ferroptosis-inducing agents. The authors showed that human islets isolated for transplantation are susceptible to erastin and RSL3-induced ferroptosis and that this can be suppressed by ferrostatin-1.

With such a background as the starting point, the examination of ferroptosis in diabetic conditions represents an intriguing and important scientific field that holds great potential for the improvement of antidiabetic therapy. Our efforts along these lines are in progress.

9. Mitochondria-Specific Strategies and Future Directions in Targeting Ferroptosis

According to the presented information related to mitochondria and ferroptosis reviewed herein, the targeting of mitochondrial metabolism presents a new concept for effective (i) antiferroptotic (cardiovascular and neurodegenerative diseases) and (ii) proferroptotic (cancer) strategies.

Considering the studies summarized in the present review, an antiferroptotic strategy that deserves more attention could be the use of specific mitochondria-targeted antioxidants. The requirement for organelle-targeted antioxidants and even more targeting of the specific site of ROS production [76] has emerged after the failure of most antioxidant therapies to achieve significant outcomes in clinical trials [141, 142]. A possible reason for this is that after in vivo application, only a small amount of antioxidant reaches cellular organelles, including the mitochondria. Thus, great effort has been invested in the design and testing of mitochondria-targeted antioxidants in a wide range of pathological conditions where mitochondrial dysfunction followed by increased mitochondrial ROS production has a significant impact [143–147].

To date, several mitochondria-targeted antioxidants have shown promise in the treatment of human pathologies such as neurodegenerative diseases [148], ischemia/reperfusion [149, 150], diabetes [151–153], hypertension [154, 155], and renal diseases [156, 157]. This list includes MitVoVitE, MitoQ, MitoTEMPO(L), and MitoLipoic acid. The beneficial effects of such compounds are commonly seen as a decrease in oxidative stress in the mitochondria and consequent improvement in the pathologies, reflected through specific parameters including tissue damage and cell death. In this context, apoptosis, as a form of mitochondria-related cell death, is well studied, and the expected benefit of targeted antioxidants has been confirmed in many cases [154, 158, 159].

Judging by the growing evidence for the involvement of mitochondrial ROS accumulation in ferroptosis in different pathological states as reviewed here, we believe that the use of antioxidants that specifically target these organelles has promising potential as an antiferroptotic strategy in many pathologies. To date, there are only a few studies that deal with the effects of mitochondria-targeted antioxidants on ferroptosis and ferroptosis-related events. In most of these studies, these antioxidants have been used as tools for examining the contribution of mitochondria to the process of ferroptosis per se [30, 35, 36], while in some recently published papers, their protective effects in several pathological conditions have been ascribed to the suppression of ferroptosis [33, 160]. Importantly, these data have paved the way for future
research directed at the development of antiferroptotic strategies in many pathological conditions.

In addition to mitochondria-targeted antioxidants, mitochondria-permeable iron chelators could be a promising approach for the suppression of mitochondrial iron overload and the consequent process of ferroptosis. DFO has commonly been used for testing the sensitivity of ferroptosis-related events in the modulation of intracellular iron. DFO is not very membrane-permeable and cannot effectively chelate intracellular iron in some tissues such as the heart [161, 162] and brain [163]. Although Dixon et al. [12] showed in the first study defining ferroptosis that membrane-permeable iron chelators such as 2,2-bipyridyl (2,2-BP) provide adequate protection against ferroptotic cell death, such that modulators of iron concentrations have not been sufficiently exploited in subsequent studies of this type of cell death. We believe that these avenues for targeting ferroptosis require attention as a therapeutic strategy in many pathological conditions. We have specifically highlighted here the issues that should be addressed in future research and that may eventually be considered potential targets in pro-/antiferroptotic therapy of the mentioned diseases, as well as in other pathological conditions accompanied by increased cell death and/or impaired mitochondrial function.

**Data Availability**

No data were used to support this study.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**Authors’ Contributions**

V.O. and A.S. conceptualized and drafted the paper. M.V. critically revised and edited the manuscript. I.G. and V.M. critically revised the manuscript.

**Acknowledgments**

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract No. 451-03-68/2020-14/200007) and by the Science Fund of the Republic of Serbia (Serbian Science and Diaspora Collaboration Program: Knowledge Exchange Vouchers, Grant No. 6525651, Ferroptosis in the β-cells death: possible strategy for diabetes treatment, acronym: BetFeSis), and this review is prepared as a starting point research for this project.

**References**

[1] https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
[2] S. A. Susin, H. K. Lorenzo, N. Zamzami et al., “Molecular characterization of mitochondrial apoptosis-inducing factor,” Nature, vol. 397, no. 6718, pp. 441–446, 1999.
[3] M. R. Duchen, “Mitochondria and calcium: from cell signalling to cell death,” The Journal of Physiology, vol. 529, no. 1, pp. 57–68, 2000.
[4] L. D. Osellame, T. S. Blacker, and M. R. Duchen, “Cellular and molecular mechanisms of mitochondrial function,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 26, no. 6, pp. 711–723, 2012.
[5] S. Javadov, A. V. Kozlov, and A. K. S. Camara, “Mitochondria in health and diseases,” Cells, vol. 9, no. 5, p. 1177, 2020.
[6] P. D. Bholaj and A. Letai, "Mitochondria–Judges and Executors of Cell Death Sentences," Molecular Cell, vol. 61, no. 5, pp. 695–704, 2016.
[7] C. B. Thompson, “Apoptosis in the pathogenesis and treatment of disease,” Science, vol. 267, no. 5203, pp. 1456–1462, 1995.

[8] N. Singh, “Apoptosis in health and disease and modulation of apoptosis for therapy: an overview,” Indian Journal of Clinical Biochemistry, vol. 22, no. 2, pp. 6–16, 2007.

[9] F. X. Sureda, F. Junyent, E. Verdague et al., “Antiangiogenic drugs: a therapeutic strategy for the prevention of neurodegenerative diseases,” Current Pharmaceutical Design, vol. 17, no. 3, pp. 230–245, 2011.

[10] K. Konstantinidis, R. S. Whelan, and R. N. Kitsis, “Mechanisms of cell death in heart disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1552–1562, 2012.

[11] A. B. Carneiro and W. S. el-Deiry, “Targeting apoptosis in cancer therapy,” Nature Reviews Clinical Oncology, vol. 17, no. 7, pp. 395–417, 2020.

[12] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012.

[13] Y. Xie, W. Hou, X. Song et al., “Ferroptosis process and function,” Cell Death & Differentiation, vol. 23, no. 3, pp. 369–379, 2016.

[14] S. Doll, B. Proneth, Y. Y. Tyurina et al., “ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition,” Nature Chemical Biology, vol. 13, no. 1, pp. 91–98, 2017.

[15] B. S. P. Shirlee Tan, B. S. P. David Schubert, and B. S. P. Pamela Maher, “Oxotyrosine: a novel form of programmed cell death,” Current Topics in Medicinal Chemistry, vol. 1, no. 6, pp. 497–506, 2001.

[16] J. Lewerenz, G. Ates, A. Meethner, M. Conrad, and P. Maher, “Oxotyrosine/ferroptosis-(Re-) emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system,” Frontiers in Neuroscience, vol. 20, no. 12, p. 214, 2018.

[17] P. Maher, A. Currais, and D. Schubert, “Using the oxotyrosine/ferroptosis pathway to understand and treat age-associated neurodegenerative diseases,” Cell Chemical Biology, vol. 27, no. 12, pp. 1456–1471, 2020.

[18] A. Linkermann, R. Skouta, N. Himmerkus et al., “Synchronized renal tubular cell death involves ferroptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16836–16841, 2014.

[19] J. P. Friedmann Angeli, M. Schneider, B. Proneth et al., “Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice,” Nature Cell Biology, vol. 16, no. 12, pp. 1180–1191, 2014.

[20] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and transferrin regulate ferroptosis,” Molecular Cell, vol. 59, no. 2, pp. 298–308, 2015.

[21] G. Gao and Y. Z. Chang, “Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases,” Frontiers in Pharmacology, vol. 5, p. 19, 2014.

[22] A. Anandhan, M. Dodson, C. J. Schmidlin, P. Liu, and D. D. Zhang, “Breakdown of an ironclad defense system: the critical role of NRF2 in mediating ferroptosis,” Cell Chemical Biology, vol. 27, no. 4, pp. 436–447, 2020.

[23] J. Li, F. Cao, H. L. Yin et al., “Ferroptosis: past, present and future,” Cell Death & Disease, vol. 11, no. 2, p. 88, 2020.

[24] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir et al., “Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease,” Cell, vol. 171, no. 2, pp. 273–285, 2017.

[25] S. Neitemeier, A. Jelinek, V. Laino et al., “BID links ferroptosis to mitochondrial cell death pathways,” Redox Biology, vol. 12, pp. 558–570, 2017.

[26] H. Wang, C. Liu, Y. Zhao, and G. Gao, “Mitochondria regulation in ferroptosis,” European Journal of Cell Biology, vol. 99, no. 1, article 151058, 2020.

[27] M. Gao, J. Yi, J. Zhu et al., “Role of mitochondria in ferroptosis,” Molecular Cell, vol. 73, no. 2, pp. 354–363.e3, 2019.

[28] T. Krainz, M. M. Gaschler, C. Lim, J. R. Sacher, B. R. Stockwell, and P. Wipf, “A mitochondrial targeted nitroxide is a potent inhibitor of ferroptosis,” ACS Central Science, vol. 2, no. 9, pp. 653–659, 2016.

[29] M. M. Gaschler, F. Hu, H. Feng, A. Linkermann, W. Min, and B. R. Stockwell, “Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis,” ACS Chemical Biology, vol. 13, no. 4, pp. 1013–1020, 2018.

[30] T. Homma, S. Kobayashi, H. Sato, and J. Fuji, “Superoxide produced by mitochondrial complex III plays a pivotal role in the execution of ferroptosis induced by cycsteine starvation,” Archives of Biochemistry and Biophysics, vol. 700, article 108775, 2021.

[31] Y. Feng, N. B. Madungwe, A. D. Imam Aliagan, N. Tombo, and J. C. Bopassa, “Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels,” Biochemical and Biophysical Research Communications, vol. 520, no. 3, pp. 606–611, 2019.

[32] Y. Q. Wang, S. Y. Chang, Q. Wu et al., “The protective role of mitochondrial ferritin on erastin-induced ferroptosis,” Frontiers in Aging Neuroscience, vol. 8, p. 308, 2016.

[33] X. X. Fang, H. Wang, D. Han et al., “Ferroptosis as a target for protection against cardiomyopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 7, pp. 2672–2680, 2019.

[34] M. G. Cotticelli, S. Xia, D. Lin et al., “Ferroptosis as a novel therapeutic target for Friedreich’s ataxia,” Journal of Pharmacology and Experimental Therapeutics, vol. 369, no. 1, pp. 47–54, 2019.

[35] A. Jelinek, L. Heyder, M. Daude et al., “Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis,” Free Radical Biology & Medicine, vol. 117, pp. 43–57, 2018.

[36] D. N. DeHart, D. Fang, K. Harrop, L. Li, J. J. Lemasters, and E. N. Maldonado, “Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells,” Biochemical Pharmacology, vol. 148, pp. 155–162, 2018.

[37] N. Kagoda, M. von Rechenberg, E. Zaganjor et al., “RAS-Raf-MEK-dependent oxidative cell death involving voltage-dependent anion channels,” Nature, vol. 447, no. 7146, pp. 864–868, 2007.

[38] R. Justo, M. Frontera, E. Pujol et al., “Gender-related differences in morphology and thermogenic capacity of brown adipose tissue mitochondrial subpopulations,” Life Sciences, vol. 76, no. 10, pp. 1147–1158, 2005.

[39] V. Petrović, A. Korać, B. Buzadžić et al., “Nitric oxide regulates mitochondrial re-modelling in interscapular brown adipose tissue: ultrastructural and morphometric-stereologic
A. Catalá and M. Díaz, “NO modulates the molecular basis of rat interscapular brown adipose tissue thermogenesis,” *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology*, vol. 152, no. 2, pp. 147–159, 2010.

B. Halliwell, “Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life,” *Plant Physiology*, vol. 141, no. 2, pp. 312–322, 2006.

N. A. Porter, “Mechanisms for the autoxidation of polyunsaturated lipids,” *Accounts of Chemical Research*, vol. 19, no. 9, pp. 262–268, 1986.

H. Feng and B. R. Stockwell, “Unsolved mysteries: how does lipid peroxidation cause ferroptosis?,” *PLOS Biology*, vol. 16, no. 5, article e2006203, 2018.

C. T. Heffern, L. Pocivavsek, A. A. Birukova et al., “Thermo-dynamic and kinetic investigations of the release of oxidized phospholipids from lipid membranes and its effect on vascular integrity,” *Chemistry and Physics of Lipids*, vol. 175-176, pp. 9–19, 2013.

J. Wong-Ekkabut, Z. Xu, W. Triampo, I. M. Tang, D. P. Tieleman, and L. Monticelli, “Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study,” *Biophysical Journal*, vol. 93, no. 12, pp. 4225–4236, 2007.

J. W. Borst, N. V. Visser, O. Kouptsova, and A. J. Visser, “Oxidation of unsaturated phospholipids in membrane bilayer mixtures is accompanied by membrane fluidity changes,” *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, vol. 1487, no. 1, pp. 61–73, 2000.

S. Dalleau, M. Baradat, F. Gueraud, and L. Huc, “Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance,” *Cell Death & Differentiation*, vol. 20, no. 12, pp. 1615–1630, 2013.

P. Chaudhary, R. Sharma, A. Sharma et al., “Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling,” *Biochemistry*, vol. 49, no. 29, pp. 6263–6275, 2010.

A. Ayala, M. F. Muñoz, and S. Argüelles, “Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal,” *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 360438, 31 pages, 2014.

Y. Zou, H. Li, E. T. Graham et al., “Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis,” *Nature Chemical Biology*, vol. 16, no. 3, pp. 302–309, 2020.

Y. Chen, Y. Liu, T. Lan et al., “Quantitative profiling of protein carbonylations in ferroptosis by an aniline-derived probe,” *Journal of the American Chemical Society*, vol. 140, no. 13, pp. 4712–4720, 2018.

W. S. Yang, R. SriRamaratnam, M. E. Welsch et al., “Regulation of ferroptotic cancer cell death by GPX4,” *Cell*, vol. 156, no. 1-2, pp. 317–331, 2014.

Y. Li, P. Maher, and D. Schubert, “A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion,” *Neuron*, vol. 19, no. 2, pp. 453–463, 1997.

R. C. Hider and X. L. Kong, “Glutathione: a key component of the cytoplasmic labile iron pool,” *BioMetals*, vol. 24, no. 6, pp. 1179–1187, 2011.

J. D. Hayes, J. U. Flanagan, and I. R. Jowsey, “Glutathione transferases,” *Annual Review of Pharmacology and Toxicology*, vol. 45, no. 1, pp. 51–88, 2005.

S. J. Dixon, D. N. Patel, M. Welsch et al., “Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis,” *eLife*, vol. 3, article e02523, 2014.

S. Dolma, S. L. Lessnick, W. C. Hahn, and B. R. Stockwell, “Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells,” *Cancer Cell*, vol. 3, no. 3, pp. 285–296, 2003.

J. B. Davis and P. Maher, “Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line,” *Brain Research*, vol. 652, no. 1, pp. 169–173, 1994.

T. H. Murphy, M. Miyamoto, A. Sastre, R. L. Schnaar, and J. T. Coyle, “Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress,” *Neuron*, vol. 2, no. 6, pp. 1547–1558, 1989.

R. Skouta, S. J. Dixon, J. Wang et al., “Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models,” *Journal of the American Chemical Society*, vol. 136, no. 12, pp. 4551–4556, 2014.

Y. Kang, S. Tiziani, G. Park, M. Kaul, and G. Paternostrro, “Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity,” *Nature Communications*, vol. 5, no. 1, p. 3672, 2014.

A. M. Battaglia, R. Chirillo, I. Aversa, A. Sacco, F. Costanzo, and F. Biamonte, “Ferroptosis and cancer: mitochondria meet the “iron maiden” cell death,” *Cells*, vol. 9, no. 6, p. 1505, 2020.

S. Torii, R. Shintoku, C. Kubota et al., “An essential role for functional lysosomes in ferroptosis of cancer cells,” *Biochemical Journal*, vol. 473, no. 6, pp. 769–777, 2016.

Y. Shen, X. Li, D. Dong, B. Zhang, Y. Xue, and P. Shang, “Transferrin receptor 1 in cancer: a new sight for cancer therapy,” *American Journal of Cancer Research*, vol. 8, no. 6, pp. 916–931, 2018.

A. Bruni, A. R. Pepper, R. L. Pawlick et al., “Ferroptosis-inducing agents compromise in vitro human islet viability and function,” *Cell Death & Disease*, vol. 9, no. 6, p. 595, 2018.

M. Dodson, R. Castro-Portuguez, and D. D. Zhang, “NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis,” *Redox Biology*, vol. 23, article 101107, 2019.

B. Daher, M. Vučetić, and J. Pouysségur, “Cysteine depletion, a key action to challenge cancer cells to ferroptotic cell death,” *Frontiers in Oncology*, vol. 10, p. 723, 2020.

E. Agmon, J. Solon, P. Bassereau, and B. R. Stockwell, “Modeling the effects of lipid peroxidation during ferroptosis on membrane properties,” *Scientific Reports*, vol. 8, no. 1, p. 5155, 2018.
C. Louandre, Z. Ezzoukhry, C. Godin et al., “Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib,” International Journal of Cancer, vol. 133, no. 7, pp. 1732–1742, 2013.

Z. Wang, M. Wang, and B. I. Carr, “Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K–cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells,” Journal of Cellular Physiology, vol. 224, no. 2, pp. 559–565, 2010.

D. R. Wise and C. B. Thompson, “Glutamate addiction: a new therapeutic target in cancer,” Trends in Biochemical Sciences, vol. 35, no. 8, pp. 427–433, 2010.

S. A. Novgorodov, J. R. Voltin, M. A. Gooz, L. Li, J. J. Lemasters, and T. I. Gudz, “Acid sphingomyelinase promotes mitochondrial dysfunction due to glutamate-induced regulated necrosis,” Journal of Lipid Research, vol. 59, no. 2, pp. 312–329, 2018.

Y. Liu and D. R. Schubert, “The specificity of neuroprotection by antioxidants,” Journal of Biomedical Science, vol. 16, no. 1, p. 98, 2009.

D. Voet and J. G. Voet, Biochemistry, J. Wiley & Sons, New York, NY, USA, 1995.

A. J. Case, S. Li, U. Basu, J. Tian, and M. C. Zimmerman, “Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II–stimulated neurons,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 305, no. 1, pp. H19–H28, 2013.

V. Adam-Vizi and L. Tretter, “The role of mitochondrial dehydrogenases in the generation of oxidative stress,” Neurochemistry International, vol. 62, no. 5, pp. 757–763, 2013.

V. Shoshan-Barmatz, D. P. Vito, M. Zweckstetter, Z. Raviv, N. Keinan, and N. Arbel, “VDAC, a multi-functional mitochondrial protein regulating cell life and death,” Molecular Aspects of Medicine, vol. 31, no. 3, pp. 227–285, 2010.

W. S. Yang and B. R. Stockwell, “Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harbor cells,” Chemistry & Biology, vol. 15, no. 3, pp. 234–245, 2008.

B. Do van, F. Gouel, A. Jonneaux et al., “Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC,” Neurobiology of Disease, vol. 94, pp. 169–178, 2016.

S. Alvarez, V. Sviderskiy, E. Terzi et al., “NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis,” Nature, vol. 551, no. 7682, pp. 639–643, 2017.

K. Bersuker, J. Hendricks, Z. Li et al., “The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis,” Nature, vol. 575, no. 7784, pp. 688–692, 2019.

T. Tadokoro, M. Ikeda, T. Ide et al., “Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin toxicity,” JCI Insight, vol. 5, no. 9, article e132747, 2020.

H. Imai and Y. Nakagawa, “Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells,” Free Radical Biology & Medicine, vol. 34, no. 2, pp. 145–169, 2003.

M. J. Hanguer, V. S. Viswanathan, M. J. Ryan et al., “Drug-tolerant persist cancer cells are vulnerable to GPX4 inhibition,” Nature, vol. 551, no. 7679, pp. 247–250, 2017.

V. S. Viswanathan, M. J. Ryan, H. D. Dhruv et al., “Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway,” Nature, vol. 547, no. 7664, pp. 453–457, 2017.

M. D. Arensman, X. S. Yang, D. M. Leahy et al., “Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 19, pp. 9533–9542, 2019.

T. Ishikawa, Y. Kajimoto, Y. Inoue, Y. Ikekami, and T. Kuroiwa, “Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor,” Advances in Cancer Research, vol. 125, pp. 197–216, 2015.

M. Buccarelli, M. Marconi, S. Pacioni et al., “Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by triggering ferroptosis,” Cell Death & Disease, vol. 9, no. 8, p. 841, 2018.

P. E. Porporato, N. Filigheddu, J. M. B.-S. Pedro, G. Kroemer, and L. Galluzzi, “Mitochondrial metabolism and cancer,” Cell Research, vol. 28, pp. 265–280, 2017.

N. Badrinnath and S. Y. Yoo, “Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy,” Carcinogenesis, vol. 39, no. 12, pp. 1419–1430, 2018.

S. W. Tait, A. Oberst, G. Quarato et al., “Widespread mitochondrial depletion via mitophagy does not compromise necroptosis,” Cell Reports, vol. 5, no. 4, pp. 878–885, 2013.

F. Ye, W. Chai, M. Xie et al., “HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRASQ61L cells,” American Journal of Cancer Research, vol. 9, no. 4, pp. 730–739, 2019.

P. Schroeder, T. Gremmel, M. Berneburg, and J. Kruttman, “Partial depletion of mitochondrial DNA from human skin fibroblasts induces a gene expression profile reminiscent of photaged skin,” Journal of Investigative Dermatology, vol. 128, no. 9, pp. 2297–2303, 2008.

K. Tomita, Y. Takashi, Y. Ouchi et al., “Lipid peroxidation increases hydrogen peroxide permeability leading to cell death in cancer cell lines that lack mtDNA,” Cancer Science, vol. 110, no. 9, pp. 2856–2866, 2019.

Y. Takashi, K. Tomita, Y. Kuwahara et al., “Mitochondrial dysfunction promotes aquaporin expression that controls hydrogen peroxide permeability and ferroptosis,” Free Radical Biology & Medicine, vol. 161, pp. 60–70, 2020.

M. Ždrálević, M. Vučetić, B. Daher, I. Marchiq, S. K. Parks, and J. Pouvyssegur, “Disrupting the ‘Warburg effect’ re-routes cancer cells to OXPHOS offering a vulnerability point via ‘ferroptosis’-induced cell death,” Advances in Biological Regulation, vol. 68, pp. 55–63, 2018.

D. F. Goldspink, J. G. Burniston, and L. B. Tan, “Cardiomyocyte death and the ageing and failing heart,” Experimental Physiology, vol. 88, no. 3, pp. 447–458, 2003.

V. Vanempel, A. Bertrand, L. Hofstra, H. Crijns, P. Doevendans, and L. Dewindt, “Myocyte apoptosis in heart failure,” Cardiovascular Research, vol. 67, no. 1, pp. 21–29, 2005.

Y. Baba, J. K. Higa, B. K. Shimada et al., “Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 314, no. 3, pp. H659–H668, 2018.

M. Jovic, A. Stancic, D. Nenadic et al., “Mitochondrial molecular basis of sevoflurane and propofol cardioprotection in patients undergoing aortic valve replacement with
cardiopulmonary bypass,” *Cellular Physiology and Biochemistry*, vol. 29, no. 1-2, pp. 131–142, 2012.

[104] M. Corral-Debrinski, T. Horton, M. T. Lott, J. M. Shoffner, M. Flint Beal, and D. C. Wallace, “Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age,” *Nature Genetics*, vol. 2, no. 4, pp. 324–329, 1992.

[105] M. P. Chen, Z. I. Cabantchik, S. Chan, G. C. Chan, and Y. F. Cheung, “Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade,” *PLoS One*, vol. 23, article e112915, 2014.

[106] N. Sumneang, N. Siri-Angkul, S. Kumfu, S. Chattipakorn, and N. Chattipakorn, “The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes,” *Archives of Biochemistry and Biophysics*, vol. 680, article 108241, 2020.

[107] M. T. Lin and M. F. Beal, “Ferroptosis is involved in acute kidney injury,” *Pathology & Oncology Research*, vol. 21, no. 4, pp. 1115–1121, 2015.

[108] N. Yamada, T. Karasawa, H. Kimura et al., “Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetalaminophen-induced acute liver failure,” *Cell Death & Disease*, vol. 11, no. 2, p. 144, 2020.

[109] J. Zhou, Y. Jin, Y. Lei et al., “Ferroptosis and acetalaminophen hepatotoxicity - are we going down another rabbit hole?,” *Gene Expression*, 2021.

[110] A. Mansouri, C.-H. Gattolliat, and T. Asselah, “Mitochondrial dysfunction and signaling in chronic liver diseases,” *Gastroenterology*, vol. 155, no. 3, pp. 629–647, 2018.

[111] R. Che, Y. Yuan, S. Huang, and A. Zhang, “Mitochondrial dysfunction in the pathophysiology of renal diseases,” *American Journal of Physiology-Renal Physiology*, vol. 306, pp. 367–378, 2014.

[112] L. Su, X. Jiang, C. Yang et al., “Pannexin 1 mediates ferroptosis that contributes to renal ischemia/reperfusion injury,” *J. Biol. Chem.*, vol. 294, no. 50, pp. 19395–19404, 2019.

[113] L.-L. Huang, X.-H. Liao, H. Sun, X. Jiang, Q. Liu, and L. Zhang, “Augmenter of liver regeneration protects the kidney from ischaemia-reperfusion injury in ferroptosis,” *Journal of Cellular and Molecular Medicine*, vol. 23, no. 6, pp. 4153–4164, 2019.

[114] M. Karaca, C. Magnan, and C. Kargar, “Masse fonctionnelle des cellules β : implication dans le diabète de type 2 et intervention thérapeutique,” *Diabetes & Metabolism*, vol. 35, no. 2, pp. 77–84, 2009.

[115] P. Marchetti and M. Masini, “Autophagy and the pancreatic beta-cell in human type 2 diabetes,” *Autophagy*, vol. 5, no. 7, pp. 1055–1056, 2009.

[116] C. E. Elswijk, T. J. Huybrechts, P. M. Delvart, and C. Brandt, “The effects of meldonium on the renal acute ischemia/reperfusion injury in rats,” *International Journal of Molecular Sciences*, vol. 20, no. 22, pp. 5749, 2019.

[117] P. Petrović, D. Bogojević, A. Koraci et al., “Oxidative stress-dependent contribution of HMGB1 to the interplay between apoptosis and autophagy in diabetic rat liver,” *Journal of Physiology and Biochemistry*, vol. 73, no. 4, pp. 511–521, 2017.

[118] A. Havasi and S. C. Borkan, “Apoptosis and acute kidney injury,” *Kidney International*, vol. 80, pp. 29–40, 2001.

[119] M. E. Guicciardi and G. J. Gores, “Apoptosis: a mechanism of acute and chronic liver injury,” *Gut*, vol. 54, no. 7, pp. 1024–1033, 2005.
of the New York Academy of Sciences, vol. 1201, no. 1, pp. 96–103, 2010.
[152] G. Mao, G. A. Kraus, I. Kim et al., "A mitochondria targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice," The Journal of Nutrition, vol. 140, no. 8, pp. 1425–1431, 2010.
[153] R. Ni, T. Cao, S. Xiong et al., "Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy," Free Radical Biology & Medicine, vol. 90, pp. 12–23, 2016.
[154] D. Graham, N. N. Huynh, C. A. Hamilton et al., "Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy," Hypertension, vol. 54, no. 2, pp. 322–328, 2009.
[155] A. E. Dikalova, A. T. Bikineyeva, K. Budzyn et al., "Therapeutic targeting of mitochondrial superoxide in hypertension," Circulation Research, vol. 107, no. 1, pp. 106–116, 2010.
[156] Y. Ishimoto, R. Inagi, D. Yoshihara et al., "Oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes," Diabetes, vol. 48, no. 4, pp. 927–932, 1999.
[157] S. I. Gorogawa, Y. Kajimoto, Y. Umayahara et al., "Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes," Diabetes Research and Clinical Practice, vol. 57, no. 1, pp. 1–10, 2002.
[158] S. Lenzen, "Oxidative stress: the vulnerable β-cell," Biochemical Society Transactions, vol. 36, no. 3, pp. 343–347, 2008.
[159] G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, "Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases," Cochrane Database of Systematic Reviews, vol. 2, article CD007176, 2008.
[160] H. M. Cochemé, C. Quin, S. J. McQuaker et al., "Measurement of H2O2 within Living Drosophila during Aging Using a Ratiometric Mass Spectrometry Probe Targeted to the Mitochondrial Matrix," Cell Metabolism, vol. 13, no. 3, pp. 340–350, 2011.
[161] B. N. Ames, M. K. Shigenaga, and T. M. Hagen, "Oxidants, antioxidants, and the degenerative diseases of aging," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, pp. 7915–7922, 1993.
[162] K. B. Beckman and B. N. Ames, "The free radical theory of aging matures," Physiological Reviews, vol. 78, no. 2, pp. 547–581, 1998.
[163] T. Finkel, "Radical medicine: treating ageing to cure disease," Nature Reviews Molecular Cell Biology, vol. 6, no. 12, pp. 971–976, 2005.
[164] K. Green, M. D. Brand, and M. P. Murphy, "Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes," Diabetes, vol. 53, Supplement 1, pp. S10–S118, 2004.
[165] H. H. Szteto, "Cell-permeable, mitochondrial-targeted, peptide antioxidants," The AAPS Journal, vol. 8, no. 2, pp. E277–E283, 2006.
[166] M. J. McManus, M. P. Murphy, and J. L. Franklin, "The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neurodegeneration in a transgenic mouse model of Alzheimer's disease," Journal of Neuroscience, vol. 31, no. 44, pp. 15703–15715, 2011.
[167] J. Neuzil, C. Widén, N. Gellert et al., "Mitochondria transmit apoptosis signalling in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury," Redox Report, vol. 12, no. 3, pp. 148–162, 2007.
[168] G. F. Kelso, A. Maroz, H. M. Cochemé et al., "A Mitochondria-Targeted Macrocyclic Mn(II) Superoxide Dismutase Mimetic," Chemistry & Biology, vol. 19, no. 10, pp. 1237–1246, 2012.
[169] R. A. J. Smith and M. P. Murphy, "Animal and human studies with the mitochondria-targeted antioxidant MitoQ," Annals of the New York Academy of Sciences, vol. 1201, no. 1, pp. 96–103, 2010.
V. Gogvadze, S. Orrenius, and B. Zhivotovsky, “Mitochondria in cancer cells: what is so special about them?,” *Trends in Cell Biology*, vol. 18, no. 4, pp. 165–173, 2008.

Q. Cui, S. Wen, and P. Huang, “Targeting cancer cell mitochondria as a therapeutic approach: recent updates,” *Future Medicinal Chemistry*, vol. 9, no. 9, pp. 929–949, 2017.

B. Kalyanaraman, G. Cheng, M. Hardy et al., “A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: therapeutic targeting of tumor mitochondria with lipophilic cationic compounds,” *Redox Biol.*, vol. 14, pp. 316–327, 2018.

J. J. Lemasters, “Evolution of voltage-dependent anion channel function: from molecular sieve to governor to actuator of ferroptosis,” *Frontiers in Oncology*, vol. 7, p. 303, 2017.